Categories
Weight Loss Products

Court Finds No Weight Loss Promises in Product Labeling

Ruling that the plaintiff failed to present sufficient evidence that a dietary supplement promised weight loss, a California federal court judge threw out a putative class action against Vitamin Shoppe.

Seeking a product that would help with weight loss, Andrea Nathan purchased a bottle of Garcinia Cambogia Extract labeled “Weight Management” and “Appetite Control” in February 2017. She later sued, alleging violations of California’s False Advertising Law (FAL), Unfair Competition Law (UCL) and Consumer Legal Remedies Act (CLRA) because the product was “nothing more than a placebo.”

Vitamin Shoppe asked the court to dismiss the suit, arguing that the label made no promises about weight loss and that it had studies to back up the statements on the product.

The court agreed and granted the motion. It was irrelevant whether the defendant could back up the statements with studies proving the active ingredients in the product resulted in weight loss “because the phrases themselves do not inherently promise weight loss benefits,” U.S. District Judge Roger T. Benitez wrote.

“The first problem with Plaintiff’s complaint is her assertion that the phrases ‘Weight Management’ and ‘Appetite Control’ equate to representations that the Product provides weight loss benefits,” the court said. “‘Weight Management’ suggests management or control of one’s weight, whose upward or downward departure may differ depending on an individual’s goals, i.e., to gain, lose, or maintain one’s weight. ‘Appetite Control’ indicates control of one’s appetite, which may or may not ultimately result in weight loss.”

Further, the plaintiff did not allege that any other statements, advertising or other communications by the defendant promoted the product as a weight loss supplement. “Instead, she merely provides her own subjective belief of the type of supplement and benefits she was looking for at the time she purchased the Product and attributed the same to the product,” the court wrote. “As a result, this alleged deficiency cannot serve as the basis for Plaintiff’s UCL, FAL, or CLRA claims.”

Judge Benitez found a second problem with the plaintiff’s complaint in her challenge to the studies upon which the defendant based its ad claims. The only conclusion regarding the representations at issue “merely states that its results ‘did not support the hypothesis that HCA supplementation may be effective on appetite and weight control by increasing fat oxidation,’” the court said. “The court finds this qualifying language is not sufficient to raise a plausible claim or falsity or a misrepresentation.”

While the court granted the defendant’s motion to dismiss, it did so without prejudice.

To read the order in Nathan v. Vitamin Shoppe, Inc., click here.

Why it matters: With a literal reading of the label, the court found that claims the product helped with “Weight Management” and “Appetite Control” did not promise weight loss, as the plaintiff maintained. Her subjective belief was insufficient to form the basis of relief under the various California statutes, the court said, granting the defendant’s motion to dismiss.

Categories
Weight Loss Products

NUTRAFUELS INC (OTCMKTS:NTFU) Stock Is Shorted Less

<!–

Stock News

–>

March 8, 2018 – By Richard Conner

The stock of NUTRAFUELS INC (OTCMKTS:NTFU) registered a decrease of 82.33% in short interest. NTFU’s total short interest was 4,100 shares in March as published by FINRA. Its down 82.33% from 23,200 shares, reported previously. The short interest to NUTRAFUELS INC’s float is 0.01%.

The stock decreased 2.84% or $0.0076 during the last trading session, reaching $0.2599. About 64,100 shares traded. NutraFuels, Inc. (OTCMKTS:NTFU) has 0.00% since March 8, 2017 and is . It has underperformed by 16.70% the SP500.

NutraFuels, Inc. manufactures and distributes oral spray nutritional and dietary products to retail and wholesale outlets. The company has market cap of $21.26 million. The companyÂ’s products include sleep spray to support a healthy sleep cycle and improve the quality of restful sleep; energize spray to enhance energy, and restore vigor and vitality; and garcinia cambogia spray, an appetite and weight management spray. It currently has negative earnings. It also offers NRG-X extreme energy spray to enhance energy and stamina; headache and pain spray to relieve headaches and pain; and hair, skin, and nails spray to nourish and encourage hair, skin, and nail growth.

More notable recent NutraFuels, Inc. (OTCMKTS:NTFU) news were published by: Marketwired.com which released: “NutraFuels, Inc. (NTFU) Launches its Oral Spray Nutraceutical Product Line …” on January 11, 2017, also Globenewswire.com with their article: “NutraFuels, Inc. (NTFU) Receives Initial Purchase Order From My Daily Choice …” published on July 29, 2015, Finance.Yahoo.com published: “NutraFuels, Inc. (NTFU) Appoints Mr. Daniel Slane to the Company’s Advisory …” on January 20, 2017. More interesting news about NutraFuels, Inc. (OTCMKTS:NTFU) were released by: Marketwired.com and their article: “NutraFuels, Inc. (NTFU) Launches New Ecommerce Site to Sell Hemp Derived …” published on June 07, 2017 as well as Marketwired.com‘s news article titled: “NutraFuels, Inc. (NTFU) Appoints Hon. Randy Avon to the Company’s Advisory Board” with publication date: February 02, 2017.

Receive News Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.

Categories
Weight Loss Products

Drug Treatment For Kidney Stones Hasn’t Changed Much In 30 Years – Until Now

Dr. Jeffrey Rimer
Dr. Jeffrey Rimer at work in the lab at the University of Houston.

In the last 30 years, not much has changed in terms of drug treatment for kidney stones. But that could be about to change.

University of Houston researcher Dr. Jeffrey Rimer and his colleagues have identified a substance that could potentially reduce kidney stone growth by 90 percent. And they’ve found some potential new molecules that could dissolve stones — or prevent them from forming altogether.

Jeffrey Rimer In The Lab
Dr. Jeffrey Rimer (left) works in the lab at the University of Houston.

Kidney stones form when the body has trouble clearing crystal-forming substances from the kidneys, such as calcium oxalate or uric acid. Or sometimes substances that prevent crystals from sticking together are absent from the urine. Either way, once crystals form and grow larger, they can become painful obstructions of urine flow.

Now, Rimer and his partners have found that the compound hydroxycitrate significantly impedes stones from growing. Hydroxycitrate is a natural component of the fruit garcinia cambogia (also known as the Malabar tamarind). If that name sounds familiar, that’s because it’s already being sold as a supplement that’s gotten a lot of press for possible weight loss benefits.

Such supplements are not studied and approved by the FDA, but, because garcinia cambogia is already on shelves, that means Rimer’s partners at NYU have already been able to start some clinical trials involving it. Once ingested, they wanted to find out whether hydroxycitrate would make it to the kidneys intact. So far, the studies have shown it does.

Jeffrey Rimer With a Student
Dr. Jeffrey Rimer (right) works in the lab at the University of Houston.

Dr. Rimer is quick to point out that it’s still far too early for anyone to run out and start taking garcinia cambogia to prevent kidney stone growth. More clinical studies are needed to determine what the best dosage would be, potential side effects, and other factors.

When it comes to developing a drug that could treat existing kidney stones — or prevent them from forming in the first place — Rimer and his associates have come across some molecules that could potentially dissolve stones or that might inhibit nucleation, which is the very first step of a crystal forming.

For his work, Rimer was recently awarded The Welch Foundation’s Norman Hackerman Award in Chemical Research.